Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Thrombin activatable fibrinolysis inhibitor,TAFI ELISA Kit

Human Thrombin activatable fibrinolysis inhibitor,TAFI ELISA Kit

  • 中文名稱：
    人纖溶抑制因子/凝血酶激活的纖溶抑制物(TAFI)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-E08778h
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
        CPB2，全名Carboxypeptidase B2，是一種蛋白酶，參與腎臟和心血管系統(tǒng)等生物過程。它主要作用是加工腎素和緩解肺動(dòng)脈高壓。CPB2在腎臟疾病、心血管疾病和炎癥等疾病中可能扮演重要角色，因此具有重要的研究價(jià)值。
        華美生物所提供的Human Thrombin activatable fibrinolysis inhibitor,TAFI ELISA Kit屬于ELISA檢測試劑盒，采用雙抗夾心法定量檢測人血漿、組織勻漿樣本中的CPB2，其靈敏度為7.81 ng/mL，檢測范圍為31.25 ng/mL-2000 ng/mL。
     
  • 別名：
    CPB2 ELISA Kit; Carboxypeptidase B2 ELISA Kit; EC 3.4.17.20 ELISA Kit; Carboxypeptidase U ELISA Kit; CPU ELISA Kit; Plasma carboxypeptidase B ELISA Kit; pCPB ELISA Kit; Thrombin-activable fibrinolysis inhibitor ELISA Kit; TAFI ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    plasma, tissue homogenates
  • 檢測范圍：
    31.25 ng/mL-2000 ng/mL
  • 靈敏度：
    7.81 ng/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Metabolism
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價(jià)

靶點(diǎn)詳情

  • 最新研究進(jìn)展：
    CPB2（Carboxypeptidase B2）是一種胰高血糖素樣酶，可以剪切肽鏈上的C端氨基酸。CPB2在血液凝血、纖溶調(diào)節(jié)和腎素-血管緊張素系統(tǒng)等生理過程中發(fā)揮重要作用。最近的研究表明，CPB2與一些腫瘤的發(fā)生和發(fā)展相關(guān)。例如，在乳腺癌和肺癌患者中，CPB2的過表達(dá)與腫瘤的惡性程度密切相關(guān)。因此，CPB2被認(rèn)為是可能的腫瘤標(biāo)志物。
     
  • 功能：
    Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down-regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin.
  • 基因功能參考文獻(xiàn)：
    1. TAFI 1040C/T could not be considered a molecular predictive factor for Recurrent spontaneous abortion in Egyptians. PMID: 28301909
    2. TAFI and TAFIa levels were increased in patients with APS as a potential response to complement activation. Interestingly, TAFI activation was associated with arterial thrombotic APS manifestations. PMID: 28669410
    3. Reprot altered in vivo TAFI activation in patients with abdominal aortic aneurysms, as shown by the increased plasma levels of TAFI(activated)/TAFIai(inactivated) and TAFI-activation peptide. PMID: 28834317
    4. Lys 42, Lys 43, Lys 44 and Arg 12 are critical for the interaction of TAFI with the thrombin-thrombomodulin complex, which modulates its antifibrinolytic potential. PMID: 28640323
    5. CPU generation during in vitro clot lysis follows a biphasic pattern in pooled plasma. A first CPU activity peak is mediated by the action of thrombin-(thrombomodulin), a second by the action of plasmin. PMID: 28692110
    6. The data suggested that suppression of TAFI by siRNA inhibits invasion and migration of breast cancer cells and that TAFI may be a new target for breast cancer therapy. PMID: 28765963
    7. Report direct crosstalk between coagulation and fibrinolysis, which takes place on activated platelets' surface that is further controlled by thrombin-activatable fibrinolysis inhibitor (TAFI). PMID: 28150854
    8. The current study revealed a significant increase level of TAFI and PAI-1, coupled with a decrease in PAI-2 in women with severe preeclampsia in comparison with the control group. PMID: 27598010
    9. The abundance of free PAI-1 and TAFI in the plaque may inhibit plasmin generation and thereby counteract plaque destabilization by fibrinolysis, cell migration and inflammation PMID: 28135035
    10. thrombin activatable fibrinolysis inhibitor pathway impairment, largely caused by a hitherto unknown TAFIa resistance, appears to be one main cause of decreased fibrinolytic resistance in FXI deficiency PMID: 27094709
    11. analysis of the a204-VHH-i83 complex, which demonstrates that two nanobodies can simultaneously bind to TAFI PMID: 27279497
    12. Sex-specific analyses explained apparent discrepancies across genetic studies of Ala147Thr and venous thrombosis. While, careful selection of genetic models based on population genetics, evolutionary and biological knowledge can increase power by decreasing the need to adjust for testing multiple models PMID: 28552956
    13. TAFIa elicited anti-angiogenic responses by endothelial cells: decreased endothelial cell proliferation, cell invasion, cell migration, tube formation, and collagen degradation. It decreased tube formation and proteolysis in endothelial cell culture grown alone and in co-culture with breast cancer cell lines. TAFIa inhibition increased secretion of matrix metalloprotease proenzymes by endothelial and breast cancer cells. PMID: 28124276
    14. Plasma levels of TAFI are elevated in patients with chronic thromboembolic pulmonary hypertension and are correlated with resistance to clot lysis in those patients. PMID: 27102961
    15. Results indicate that TAFIa could be a novel biomarker and realistic therapeutic target of chronic thromboembolic pulmonary hypertension. PMID: 28289017
    16. R12 is a critical residue for the activation of TAFI by thrombin-thrombomodulin PMID: 26816270
    17. Thrombin activatable fibrinolysis inhibitor, particularly its preoperative levels but also levels during the immediate postoperative period, may be key for understanding coagulopathy during liver transplantation, and it may have a role as predictor of increased mortality rates in the liver transplant population PMID: 27410412
    18. The results suggest that although the TAFI S438G>T polymorphism is not correlated with venous thrombosis risk in all genetic models of venous thrombosis, a trend toward a reduced risk still could be observed. (Meta-analysis) PMID: 26656901
    19. rs3742264 and rs1926447 have a modest effect on susceptibility to cardiovascular and cerebrovascular diseases. PMID: 27173177
    20. The results of the present study demonstrated that the CPB2 expression in patients with chronic hepatitis C was inversely correlated with several risk factors of hepatic fibrosis or steatosis, although ectopic CPB2 expression did not suppress the expression of fibrogenic or lipogenic genes. PMID: 27094832
    21. Protein C and TAFI are concurrently activated in a thrombomoulin-dependent manner and do not compete for the thrombin-TM complex, raising the possibility that they interact with distinct activation complexes. PMID: 26663133
    22. Acute myocardial infarction patients have higher plasma CPU levels and lower proCPU levels than controls. This finding indicates in vivo generation of functional active CPU in patients with AMI. PMID: 26340515
    23. Arg12-Glu28 and Cys383-Val401 in TAFI are involved in thrombomodulin-mediated TAFI activation. Gly205-Asp232 is involved in binding to thrombin. PMID: 26341360
    24. CPB2 polymorphisms (reference sequences: rs1926447 and rs3742264) were related to systemic complications in bacterial meningitis. TAFI levels correlated positively with CSF complement. rs1926447 (TT) was associated with higher levels of TAFI in CSF. PMID: 26340319
    25. Pro-inflammatory cytokines or lipopolysaccharide decreased TAFI protein levels via binding of tristetraprolin to the CPB2 3'-UTR, which mediates CPB2 mRNA destabilisation. HuR can bind the CBP2 3'UTR. This is reduced by pro-inflammatory mediators. PMID: 26062599
    26. Review/Meta-analysis: failed to confirm the influence of Ala147Thr and Thr325Ile TAFI variants on the susceptibility to CVD. Increased risk of CHD was detected in TAFI Ile325 allele carriers. PMID: 25042727
    27. TAFI deficiency results in increased brain damage in a model of thrombolysis after ischemic stroke, which was not associated with bleeding but with neuronal degeneration and MP production. PMID: 26118976
    28. Generated stable deletion mutant of TAFI with full carboxypeptidase activity without activation. PMID: 25773535
    29. the associations between three TAFI variants -438G/A, 505G/A and 1040C/T and the risk of venous thrombosis; there was a significant association between 505G/A and the risk of disease (Meta-Analysis) PMID: 26071134
    30. PAI-1 4G/5G polymorphism does not have any effect on occurrence of intracranial and extracranial hemorrhages in patients with FXIII deficiency, while TAFI Thr325Ile is a strong genetic risk factor. PMID: 25001244
    31. High plasma TAFI level is associated with the increasing risk of T2DM. PMID: 25396763
    32. We have demonstrated that TAFI might be a risk factor for the development of SCF independently of conventional cardiovascular risk factors. PMID: 24068025
    33. Arg12 of TAFI plays an important role in thrombomodulin-mediated TAFI activation by thrombin PMID: 25066897
    34. Neither intact TAFI nor activation peptide of TAFI can discriminate venous thromboembolism patients from healthy controls. PMID: 25193405
    35. High level of TAFI antigen in attack-free period of familial Mediterranean fever shows ongoing subclinical inflammation and hypercoagulability. PMID: 24580410
    36. TAFI levels are independently associated to dyslipidemia and that the polymorphism rs3742264 may be related to cardiovascular risk in male subjects PMID: 24631134
    37. Study provides preliminary evidence that the TAFI -2345 2G/1G and -1690 A/G polymorphisms are associated with ACI susceptibility in a Han Chinese population. PMID: 24886076
    38. inhibition of TAFIa activity, however, was substrate-specific, because neither mAb inhibited the cleavage of thrombin-activated osteopontin and C5a by TAFIa, thus sparing the anti-inflammatory activity of TAFIa PMID: 24134522
    39. Augmentation of clot formation and anti-fibrinolysis by combining fib, FXIII and TAFI may be beneficial for the treatment of patients with severe thrombocytopenia PMID: 24333083
    40. Our data indicate that the GTC haplotype for TAFI 505G>A/1040C>T/+1542C>G SNPs increased the risk of CVT in comparison to controls and VTE cases. PMID: 24252537
    41. A significant correlation was present between TAFI Thr325Ile polymorphism in homozygous form and occurrence of spontaneous intracranial haemorrhage. PMID: 24354489
    42. Plasma TAFI levels and TAFI Thr325Ile genotypes were associated with breast cancer patients in Chinese Han populations and could be considered as the risk indicators of breast cancer. PMID: 23624357
    43. TAFI expression in HepG2 cells is reduced by nobiletin, a polymethoxyflavone in citrus fruits, through transcriptional inhibition PMID: 23572161
    44. TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity PMID: 23595589
    45. Our study is the first in the literature to determine increased TAFI levels in primary hypertension patients. PMID: 22799880
    46. This pilot study shows that TAFI levels are inversely correlated with inflammation-associated development of complications after major trauma. PMID: 22749979
    47. Plasma TAFI antigen levels were significantly higher in pregnant women with gestational diabetes mellitus when compared with controls. PMID: 23327722
    48. Oral anticoagulants enhance both plasma and blood fibrinolysis by reducing thrombin-dependent TAFI activation, a phenomenon largely determined by low prothrombin levels. PMID: 23256818
    49. Alterations of TAFIa-dependent prolongation of clot lysis in patients with thyroid disorders may cause an impaired haemostatic balance. PMID: 23197299
    50. High neutrophil elastase, low TAFI activity and PPIC in disseminated intravascular coagulation are independent predictors of patient death and MODS. PMID: 22353215

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Secreted.
  • 蛋白家族：
    Peptidase M14 family
  • 組織特異性：
    Plasma; synthesized in the liver.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 2300

    OMIM: 603101

    KEGG: hsa:1361

    STRING: 9606.ENSP00000181383

    UniGene: Hs.512937